Key result
Oral prednisone plus BMS cuts major events ~55% vs. BMS alone.
Why the study?
To analyse the 4-year clinical outcomes in patients with coronary artery disease treated with BMS alone versus BMS plus oral prednisone versus DES.
Does oral prednisone plus BMS or DES improve event-free survival compared to BMS alone in non-diabetic ischaemic patients undergoing percutaneous coronary intervention?
RCT (n=375)
randomized
Yes
Does oral prednisone plus BMS or DES improve event-free survival compared to BMS alone in non-diabetic ischaemic patients undergoing percutaneous coronary intervention?
Oral prednisone plus bare metal stents provides sustained clinical benefits over bare metal stents alone at 4 years, with fewer very late stent thromboses compared to drug-eluting stents.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“immunosuppressive therapy may be an option for patients who require stenting, but it should be reserved for a very select group. The study provides good news that if you're careful about selection of patients you can end up without any major side effects and relatively acceptable results.”
“this strategy may help patients (and doctors) in situations of economic restrictions wherever the cost of DES is still an issue.”
Prednisone plus BMS may sustain event-free survival gains versus BMS alone in non-diabetics; leaves open durable DES equivalence without very late thrombosis.
AIMS: To analyse the clinical outcome at 4 years in patients with coronary artery disease treated with bare metal stents (BMS) vs. BMS and oral prednisone, or drug-eluting stents (DES), all assuming similar adjunctive medical treatment. METHODS AND RESULTS: Five Italian hospitals enrolled 375 non-diabetic, ischaemic patients without contraindications to dual anti-platelet treatment or corticosteroid therapy in a randomized controlled study. The primary endpoint was the event-free survival of cardiovascular death, myocardial infarction, and recurrence of ischaemia needing repeated target vessel revascularization at 1 year, and this was significantly lower in the BMS group (80.8%) compared with the prednisone (88.0%) and DES group (88.8%, P = 0.04 and 0.006, respectively). The long-term analysis of the primary endpoint was a pre-specified aim of the trial, and was performed at 1447 days (median, IQ range = 1210-1641). Patients receiving BMS alone had significantly lower event-free survival (75.3%) compared with 84.1% in the prednisone group (HR: 0.447; 95% CI: 0.25-0.80, P = 0.007) and 80.6% in DES patients (HR: 0.519; 95% CI: 0.29-0.93, P = 0.03). Prednisone-treated patients did not develop new treatment-related clinical problems. Drug-eluting stents patients suffered more very late stent thrombosis as a cause of spontaneous myocardial infarction. The need for target vessel revascularization remained lower in the prednisone and DES groups (13.6 and 15.2%, respectively), compared with BMS (23.2%). CONCLUSIONS: The clinical benefits of prednisone compared with BMS only persisted almost unchanged at 4 years. Drug-eluting stents performed better than BMS at long-term, although the advantages observed at 1 year were in part attenuated because of the occurrence of very late stent thrombosis and late revascularizations. Clinical Trial NCT 00369356.
No takes yet. Share an insight, caveat, or question.
Zivelonghi et al. (2013) conducted an RCT in coronary artery disease (n=375). Oral prednisone plus bare metal stents vs. Bare metal stents alone was evaluated on event-free survival of cardiovascular death, myocardial infarction, and recurrence of ischaemia needing repeated target vessel revascularization (HR 0.447, 95% CI 0.25-0.80, p=0.007). Oral prednisone plus bare metal stents improved long-term event-free survival compared with bare metal stents alone.
Synapse has enriched 10 related papers. Consider them for comparative context: